Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents

Waleed Ghanima, Peter Junker, Hans Carl Hasselbalch, Leonardo Boiocchi, Julia T. Geyer, Xingmin Feng, Sif Gudbrandsdottir, Attilio Orazi, James B. Bussel

Research output: Contribution to journalArticlepeer-review


This study assessed the grade of bone marrow (BM) fibrosis and its association with a seromarker for collagen-III formation and fibrosis-related cytokines in 25 immune thrombocytopenia (ITP) patients treated with thrombopoietin receptor agonists (Tpo-RA) who had at least one BM biopsy. Assessment of 8 pre- and on-treatment BM biopsies revealed statistically significant increases in reticulin. Reticulin in biopsies performed after a median of 1·4years of treatment was graded: MF-0 in 3 (12%), MF-1 in 19 (76%), MF-2 in 2 (8%) and MF-3 in 1 (4%). No cytogenetic or flow-cytometric abnormalities were detected. Median pretreatment Procollagen III N-propeptide (PIIINP) (6·6μg/l) was significantly higher than on-treatment levels (5·6μg/l); both were higher than controls (3·4μg/l; P

Original languageEnglish
Pages (from-to)248-255
Number of pages8
JournalBritish Journal of Haematology
Issue number2
Publication statusPublished - Oct 2011


  • Hepatocyte growth factor
  • Myelofibrosis
  • Platelets
  • Procollagen
  • Transforming growth factor beta (TGF-β)

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents'. Together they form a unique fingerprint.

Cite this